Active, not recruitingPhase 3NCT05648968
A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia
Studying Autoimmune hemolytic anemia, warm type
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Novartis Pharmaceuticals
- Principal Investigator
- Novartis PharmaceuticalsNovartis Pharmaceuticals
- Intervention
- Ianalumab(biological)
- Enrollment
- 90 enrolled
- Eligibility
- 18-100 years · All sexes
- Timeline
- 2022 – 2028
Study locations (30)
- Michigan Center of Medical Research, Farmington Hills, Michigan, United States
- University of Minnesota Med Center, Minneapolis, Minnesota, United States
- Fred Hutchinson Cancer Center, Seattle, Washington, United States
- Novartis Investigative Site, CABA, Buenos Aires, Argentina
- Novartis Investigative Site, Caba, Argentina
- Novartis Investigative Site, Garran, Australian Capital Territory, Australia
- Novartis Investigative Site, Melbourne, Victoria, Australia
- Novartis Investigative Site, Guangzhou, Guangdong, China
- Novartis Investigative Site, Hangzhou, Zhejiang, China
- Novartis Investigative Site, Dalian, China
- Novartis Investigative Site, Tianjin, China
- Novartis Investigative Site, Créteil, France
- Novartis Investigative Site, Lille, France
- Novartis Investigative Site, Nantes, France
- Novartis Investigative Site, Nice, France
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05648968 on ClinicalTrials.govOther trials for Autoimmune hemolytic anemia, warm type
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07039422Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From IanalumabNovartis Pharmaceuticals
- RECRUITINGEARLY PHASE1NCT07530380UCAR T-cell Therapy Targeting CD19/BCMA in Relapsed/Refractory Autoimmune Hemolytic AnemiaThe Second Hospital of Anhui Medical University
- RECRUITINGNANCT05925023Sirolimus in the Treatment of Refractory/Relapsed wAIHAPeking Union Medical College Hospital
- ACTIVE NOT RECRUITINGPHASE2NCT05002777Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA)Sanofi
- ACTIVE NOT RECRUITINGPHASE2NCT04657094Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic LeukemiaCity of Hope Medical Center